1 ML octreotide 0.5 MG/ML Injection — RxCUI 312070
RxNorm drug concept · Semantic clinical drug
RxCUI 312070
Semantic clinical drug · SCD
● Current RxNorm concept 31 FDA products
31 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI312070
Official name1 ML octreotide 0.5 MG/ML Injection
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known as1 ML octreotide 500 MCG/ML Injection; octreotide 500 MCG in 1 ML Injection; octreotide 500 MCG per 1 ML Injection
FDA products mapped31
Package NDCs mapped31
Reported Medicaid activity (SDUD)2,019 prescriptions · 22 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Octreotide: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- Octreotide works like a more powerful version of a natural hormone in your body called somatostatin. Depending on what it's prescribed for, it either lowers your growth hormone lev...
- What exactly does octreotide do — and why do I need it?
- Yes, timing around food matters a lot with Mycapssa. You need to take it on a completely empty stomach — at least one hour before you eat anything, or at least two hours after your...
- How do I take Mycapssa correctly — does it matter if I eat first?
🕸️ Concept Web — How 1 ML octreotide 0.5 MG/ML Injection Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
1 ML octreotide 0.5 MG/ML Injection
RxCUI 312070 Semantic clinical drug · SCD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 1
The active substance itself — no strength, form, or brand attached yet.
-
Octreotide
7617IN
-
Octreotide
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Sandostatin
196457BN
-
Sandostatin
-
Dose forms 6
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Octreotide Injection
1654342SCDF -
Octreotide Injectable Product
1160449SCDG -
Octreotide Injection [Sandostatin]
1654344SBDF -
Sandostatin Injectable Product
1185966SBDG -
Injection
1649574DF -
Injectable Product
1151126DFG
-
Octreotide Injection
-
Clinical & branded drugs 3
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Octreotide 0.5 MG/ML
328444SCDC -
1 ML octreotide 0.5 MG/ML Injection [Sandostatin]
207200SBD -
Octreotide 0.5 MG/ML [Sandostatin]
567991SBDC
-
Octreotide 0.5 MG/ML
Showing up to 8 concepts per family — 11 of 11 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Octreotide 0.5 MG/ML
SCDC · 328444 -
Octreotide Injection
SCDF · 1654342 -
Octreotide Injectable Product
SCDG · 1160449
Brand-Name Concepts
-
1 ML octreotide 0.5 MG/ML Injection [Sandostatin]
SBD · 207200 -
Octreotide 0.5 MG/ML [Sandostatin]
SBDC · 567991 -
Octreotide Injection [Sandostatin]
SBDF · 1654344 -
Sandostatin Injectable Product
SBDG · 1185966 -
Sandostatin
BN · 196457
📦 FDA Products & Package NDCs
31 products · 31 package NDCs
31 package NDCs map to RxCUI 312070 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 00078-0180-01 | 10 AMPULE in 1 PACKAGE (0078-0180-01) / 1 mL in 1 AMPULE (0... | Sandostatin | Novartis Pharmaceuticals Corporation | 1988-10-21 |
| 00078-0181-01 | 10 AMPULE in 1 PACKAGE (0078-0181-01) / 1 mL in 1 AMPULE (0... | Sandostatin | Novartis Pharmaceuticals Corporation | 1988-10-21 |
| 00078-0182-01 | 10 AMPULE in 1 PACKAGE (0078-0182-01) / 1 mL in 1 AMPULE (0... | Sandostatin | Novartis Pharmaceuticals Corporation | 1988-10-21 |
| 00641-6174-10 | 10 VIAL, SINGLE-DOSE in 1 CARTON (0641-6174-10) / 1 mL in 1... | Octreotide Acetate | Hikma Pharmaceuticals USA Inc. | 2005-04-04 |
| 00641-6175-10 | 10 VIAL, SINGLE-DOSE in 1 CARTON (0641-6175-10) / 1 mL in 1... | Octreotide Acetate | Hikma Pharmaceuticals USA Inc. | 2005-04-04 |
| 00641-6176-10 | 10 VIAL, SINGLE-DOSE in 1 CARTON (0641-6176-10) / 1 mL in 1... | Octreotide Acetate | Hikma Pharmaceuticals USA Inc. | 2005-04-04 |
| 00641-6177-01 | 1 VIAL, MULTI-DOSE in 1 CARTON (0641-6177-01) / 5 mL in 1 V... | Octreotide Acetate | Hikma Pharmaceuticals USA Inc. | 2005-04-08 |
| 00641-6178-01 | 1 VIAL, MULTI-DOSE in 1 CARTON (0641-6178-01) / 5 mL in 1 V... | Octreotide Acetate | Hikma Pharmaceuticals USA Inc. | 2005-04-08 |
| 23155-0685-31 | 5 mL in 1 VIAL, GLASS (23155-685-31) | OCTREOTIDE ACETATE | Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. | 2022-05-25 |
| 23155-0686-31 | 5 mL in 1 VIAL, GLASS (23155-686-31) | OCTREOTIDE ACETATE | Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. | 2022-05-25 |
| 23155-0687-41 | 10 VIAL, GLASS in 1 CARTON (23155-687-41) / 1 mL in 1 VIAL,... | OCTREOTIDE ACETATE | Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. | 2022-05-25 |
| 23155-0688-41 | 10 VIAL, GLASS in 1 CARTON (23155-688-41) / 1 mL in 1 VIAL,... | OCTREOTIDE ACETATE | Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. | 2022-05-25 |
| 23155-0689-41 | 10 VIAL, GLASS in 1 CARTON (23155-689-41) / 1 mL in 1 VIAL,... | OCTREOTIDE ACETATE | Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. | 2022-05-25 |
| 25021-0463-01 | 10 VIAL in 1 CARTON (25021-463-01) / 1 mL in 1 VIAL | Octreotide Acetate | Sagent Pharmaceuticals | 2023-06-15 |
| 25021-0464-01 | 10 VIAL in 1 CARTON (25021-464-01) / 1 mL in 1 VIAL | Octreotide Acetate | Sagent Pharmaceuticals | 2023-06-15 |
| 25021-0465-01 | 10 VIAL in 1 CARTON (25021-465-01) / 1 mL in 1 VIAL | Octreotide Acetate | Sagent Pharmaceuticals | 2023-06-15 |
| 25021-0466-05 | 1 VIAL in 1 CARTON (25021-466-05) / 5 mL in 1 VIAL | Octreotide Acetate | Sagent Pharmaceuticals | 2023-06-15 |
| 25021-0467-05 | 1 VIAL in 1 CARTON (25021-467-05) / 5 mL in 1 VIAL | Octreotide Acetate | Sagent Pharmaceuticals | 2023-06-15 |
| 63323-0376-01 | 10 VIAL, SINGLE-DOSE in 1 TRAY (63323-376-01) / 1 mL in 1 V... | Octreotide | Fresenius Kabi USA, LLC | 2006-03-14 |
| 63323-0376-04 | 10 VIAL, SINGLE-DOSE in 1 TRAY (63323-376-04) / 1 mL in 1 V... | Octreotide | Fresenius Kabi USA, LLC | 2006-03-14 |
| 63323-0377-01 | 10 VIAL, SINGLE-DOSE in 1 TRAY (63323-377-01) / 1 mL in 1 V... | Octreotide | Fresenius Kabi USA, LLC | 2006-03-14 |
| 63323-0377-04 | 10 VIAL, SINGLE-DOSE in 1 TRAY (63323-377-04) / 1 mL in 1 V... | Octreotide | Fresenius Kabi USA, LLC | 2006-03-14 |
| 63323-0378-05 | 1 VIAL, MULTI-DOSE in 1 CARTON (63323-378-05) / 5 mL in 1 V... | Octreotide | Fresenius Kabi USA, LLC | 2006-03-14 |
| 63323-0379-05 | 1 VIAL, MULTI-DOSE in 1 CARTON (63323-379-05) / 5 mL in 1 V... | Octreotide | Fresenius Kabi USA, LLC | 2006-03-14 |
| 68083-0517-10 | 10 VIAL in 1 CARTON (68083-517-10) / 1 mL in 1 VIAL | Octreotide Acetate | Gland Pharma Limited | 2023-06-22 |
| 68083-0560-10 | 10 VIAL in 1 CARTON (68083-560-10) / 1 mL in 1 VIAL | Octreotide Acetate | Gland Pharma Limited | 2023-06-22 |
| 68462-0896-10 | 10 VIAL in 1 CARTON (68462-896-10) / 1 mL in 1 VIAL (68462-... | Octreotide Acetate | GLENMARK PHARMACEUTICALS INC., USA | 2023-08-09 |
| 68462-0897-10 | 10 VIAL in 1 CARTON (68462-897-10) / 1 mL in 1 VIAL (68462-... | Octreotide Acetate | GLENMARK PHARMACEUTICALS INC., USA | 2023-08-09 |
| 71288-0566-02 | 10 VIAL, SINGLE-DOSE in 1 CARTON (71288-566-02) / 1 mL in 1... | Octreotide Acetate | Meitheal Pharmaceuticals, Inc. | 2025-02-28 |
| 71288-0567-02 | 10 VIAL, SINGLE-DOSE in 1 CARTON (71288-567-02) / 1 mL in 1... | Octreotide Acetate | Meitheal Pharmaceuticals, Inc. | 2025-02-28 |
| 71288-0568-02 | 10 VIAL, SINGLE-DOSE in 1 CARTON (71288-568-02) / 1 mL in 1... | Octreotide Acetate | Meitheal Pharmaceuticals, Inc. | 2025-02-28 |
Observed labelers:
Fresenius Kabi USA, LLC (6) ·
Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. (5) ·
Hikma Pharmaceuticals USA Inc. (5) ·
Sagent Pharmaceuticals (5) ·
Meitheal Pharmaceuticals, Inc. (3) ·
Novartis Pharmaceuticals Corporation (3)
· +2 more — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🧾 Billing Codes (HCPCS)
Medical billing codes (HCPCS "J-codes") that connect to this concept's packages — used mostly when a clinic or hospital bills for a drug it administers. Each code links to its full billing page.
| Code | Descriptor | Mapped packages | Sources |
|---|---|---|---|
| J2354 | Octreotide inj, non-depot | 29 | CMS |
⚠ A crosswalk is not coverage: an NDC↔HCPCS mapping does not guarantee any payer covers or pays the code. Always verify the current payer policy before billing.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.